

AD _____

AD-A230 244**CONTRACT NO: DAMD17-86-C-6015****TITLE: RESEARCH ON DEFENSE AGAINST THE EFFECTS OF
PARASITIC DISEASE****Subtitle: Pilot Study on the Efficacy of Pentostam in the
Treatment of Mucocutaneous Leishmaniasis (MCL)****PRINCIPAL INVESTIGATOR: Rolando E. Sáenz, M.D.****CONTRACTING ORGANIZATION: Gorgas Memorial Institute of Tropical
and Preventive Medicine, Inc.
9650 Rockville Pike
Bethesda, MD 20814****REPORT DATE: November 1, 1990****TYPE OF REPORT: Final Report****PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012****DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited**

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

DTIC
ELECTE
DEC 27 1990
S B D
C

00 12 26 073

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution unlimited		
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE					
4. PERFORMING ORGANIZATION REPORT NUMBER(S)			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
6a. NAME OF PERFORMING ORGANIZATION Gorgas Memorial Institute of Tropical & Preventive Medicine,		6b. OFFICE SYMBOL (if applicable) Inc.	7a. NAME OF MONITORING ORGANIZATION		
6c. ADDRESS (City, State, and ZIP Code) 9650 Rockville Pike Bethesda, MD 20814			7b. ADDRESS (City, State, and ZIP Code)		
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command		8b. OFFICE SYMBOL (if applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Contract No. DAMD17-86-C-6015		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21702-5012			10. SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO. --	PROJECT NO. --	TASK NO. --
11. TITLE (Include Security Classification) Research on Defense Against the Effects of Parasitic Disease					
12. PERSONAL AUTHOR(S) Rolando E. Saenz, M.D.					
13a. TYPE OF REPORT Final Report		13b. TIME COVERED FROM 4/15/86 TO 8/14/89		14. DATE OF REPORT (Year, Month, Day) 1990 November 1	
15. PAGE COUNT 13					
16. SUPPLEMENTARY NOTATION Subtitle: Pilot Study on the Efficacy of Pentostam in the Treatment of Mucocutaneous Leishmaniasis (MCL)					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP	Antiparasitic Drugs, Drugs, Infectious Diseases, Ketoconazole, Leishmaniasis, Parasitic Diseases, RA I, Leishmaniasis, Animals, Volunteers. (55) ✓		
--	--	--			
--	--	--			
19. ABSTRACT (Continue on reverse if necessary and identify by block number) A study to determine the value of intravenous administration of sodium stibogluconate (Pentostam) for treatment of mucocutaneous leishmaniasis, involved 16 patients, 9 females and 7 males. The dose was 20 mg/kg body weight for 28 days. Thirteen patients completed the full course, while in 3 treatment was interrupted due to adverse side effects, such as cardiac alterations, elevation of transaminases, vomiting, arthralgias and myalgias. Of the 13 patients who completed treatment, ten were healed, and no relapses appeared in follow-up periods of 9-15 months. One was completely healed at the end of treatment and the others healed more slowly; they were considered healed after 6-11 months.					
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT. ☐ DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION		
22a. NAME OF RESPONSIBLE INDIVIDUAL Mrs. Virginia M. Miller			22b. TELEPHONE (Include Area Code) (301) 663-7325		22c. OFFICE SYMBOL SGRD-RMI-S

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 45CFR46.

for Rolando Sáenz, M.D., P.I.

PI Signature

12/21/90

Date

Leon Jacobs, Ph.D., Chairman and President
Gorgas Memorial Institute

DISTRIBUTION LIST

5 copies

Director
Walter Reed Army Institute of Research
Walter Reed Army Medical Center
ATTN: SGRD-UWZ-C
Washington, DC 20307-5100

1 Copy

Commander
US Army Medical Research and Development Command
ATTN: SGRD-RMI-S
Fort Detrick, Frederick, Maryland 21702-5012

2 copies

Defense Technical Information Center (DTIC)
ATTN: DTIC-FDAC
Cameron Station
Alexandria, VA 22304-6145

1 copy

Dean
School of Medicine
Uniformed Services University of the
Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799

1 copy

Commandant
Academy of Health Sciences, US Army
ATTN: AHS-CDM
Fort Sam Houston, TX 78234-6100

Accession For	
NTIS GRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

Studies of the therapeutic value of sodium stibogluconate (Pentostam) in the treatment of mucocutaneous leishmaniasis (MCL) were continued thru FY '89.

From December 1987 to February 1990, 16 patients with MCL were enrolled in the study. Nine were female and 7 male. The majority (13/16) were between the ages of 18 to 33 years old. They came from rural communities of endemic cutaneous leishmaniasis (CL) in the Provinces of Panama, Colón, Coclé and Chiriquí. Four of the 16 patients had had treatment for leishmaniasis. Ten had no previous treatment, and two did not know if they had any treatment.

In 5/16 patients the mucosal involvement occurred during the primary cutaneous infection, four by direct extension from the lesion on the nose, and one presumably through metastases from an active cutaneous lesion on the leg. In eight patients the mucosal lesion occurred 8 to 58 years after the primary infection. Upon physical examination, 8 of the 16 patients had the characteristic hypopigmented and depressed scars of healed CL. The lack of scars or active lesions in three patients suggests that subclinical or minimal initial CL may also lead to MCL.

The infection was located in the nasal mucosa in all patients and was considered moderate in 10 and mild in 6 (definition: mild, when the infection is localized in the nasal mucosa and is less than 1.5 cm in diameter; moderate,

when there is a perforated septum or a localized lesion in the nasal mucosa of more than 1.5 cm; severe, when there is involvement of more than one anatomical area, nasal, oropharynx, larynx and the presence of extensive destructive lesions).

The nasal septum (15/16), and the inferior turbinate (8/16) were the most common sites for the infection. No extension of the disease beyond the nasal structure was seen (i.e. nasal structures and oral pharynx, oral cavity, larynx, etc.). (Table 1)

Granulomatous lesions were observed in 10/16 patients, ulceration in 5/16 patients, perforation of the septum in 1/16 patients and marked atrophy of the inferior turbinate in 2/16 (Table 2).

Nasal obstruction 16/16, epistaxis 7/16, rhinorrhea 7/16 and itching 6/16 were the most common presenting symptoms (Table 3).

The Montenegro skin test and the serology by indirect immuno fluorescence (IFA) were positive in all patients. The direct smear of biopsy material was positive in 8/16, biopsy in 1/5, and isolation of parasites by culture was positive in 4/16. The four isolates were characterized by isoenzyme electrophoresis as Leishmania panamensis.

Hospitalized patients were treated with Pentostam (intravenously), 20 mg per kg of body weight daily for 28

days. Thirteen patients completed the full course of treatment, and in three, treatment was interrupted due to toxicity. The following adverse effects were considered drug associated: arthralgias in 10/16, myalgias 9/16, leucopenia with neutropenia in 5/16 and transient elevation of transaminase in 7/16. ECG abnormalities were detected in 7/16 patients and these include: first degree A-V block in one, premature ventricular contractions in one and changes in ventricular depolarization in five. There was no prolongation of Q-T interval (Table 4). The ECG changes returned to normal after treatment was stopped.

After discharge from the hospital, all 16 patients have been under evaluation in the ENT Clinic of Santo Tomas Hospital, as well as in the GML Clinic.

Three patients did not complete treatment because of toxic reactions. One, a 32 year-old male (WR-13) developed cardiac alterations (premature ventricular contractions and ischemic changes in the left ventricle) after 21 days of therapy at which time treatment was suspended. The patient left the hospital and has not returned.

A second patient, female, 70 years-old (WR-15), developed cardiac alteration after 14 days of therapy. The patient also developed fever, nausea, diarrhea, anorexia, and ECG minimal changes of repolarization. No improvement of the mucosal lesion was observed. Therapy was discontinued and the subsequent follow up at 10 months shows some progression of the infection.

A third patient, female, 32 years-old (WR-11), was treated for 13 days, and developed severe headache, myalgia, arthralgia, liver enzyme increase to GOT 126, GPT 120, and neutropenia with a white blood cell decrease to 2,294. At this time there was no improvement in the lesion, and treatment was terminated. At the end of 13 months follow up, parasites were still present.

Thirteen patients received the full course of therapy. Of these, three were considered failures; one (WR-2), a 23 year-old female never showed improvement of the lesion and has remained parasitologically positive after 15 months. A second patient (WR-4), a 29 year-old male was considered healed after 3 months, but at the 12 month follow-up, the lesion appeared active and amastigotes of Leishmania were demonstrated in smears.

The third patient (WR-12), a 24 years-old female was considered healed at 7 months follow-up, but at 13 months there was a return of symptoms and a reactivation of the nasal lesion. The presence of parasites have not been confirmed.

Of the remaining 10 patients who received the full course of treatment, the ENT evaluation in five patients showed complete healing, after 12 to 15 months; and in five patients, after 9 to 11 months. The time of healing varied from the termination of treatment (one patient) to 6 to 11 months (9 patients).

COMMENTS:

This study designed to determine the value of intravenous sodium stibogluconate (Pentostam) in the treatment of MCL, has been concluded. During the period December 1987 to August 1989, 16 patients were studied, 9 females and 7 males.

These patients came from widely separated regions representing most of the endemic areas of leishmaniasis in the Republic of Panama.

It is of interest to note that in this group of MCL patients, the female outnumbered the males, in contrast to the cutaneous disease, in which the males greatly outnumber the females. This difference suggests a possible risk factor. The lack of specific parenteral therapy also represents a definite risk factor due to the fact that spread of the parasites beyond the primary lesion, occurs commonly along lymphatics and less commonly by the blood stream. Therefore, the practice of application of cauterizing agents, infiltration of the lesion by antimonial compounds, and the application of heat are not adequate. In this series, 12 of the 16 patients had no history of specific parenteral therapy.

We have demonstrated two types of MCL, one representing a long term complication of the previous cutaneous lesion and the other occurring simultaneously with the cutaneous

disease; in the latter, either as a result of direct extension of the cutaneous lesion or as a metastatic phenomenon.

The clinical symptoms and physical findings have been discussed. The constant physical findings were the involvement of the septum and the inferior turbinate. The middle and superior turbinate were never involved.

Four isolates have been identified as Leishmania panamensis from this series of patients. Five additional isolates have been obtained from patients with MCL, not included in this study, and have been identified also as L. panamensis, indicating that this species is probably responsible for MCL in Panama.

In thirteen of the patients, Pentostam was relatively well tolerated, but in three therapy had to be terminated because of toxic reactions which included cardiac, alterations, elevation of transaminases, vomiting, arthralgias and myalgias.

Of the thirteen patients who received the complete course of therapy, three were considered treatment failures, one which never showed improvement and two in which a relapse occurred at 12 and 13 months.

Of the ten patients that completed therapy and healed, one appeared healed at the end of treatment and has remained

healed after a 15-month follow up. The remaining 9 patients were considered healed after periods of 6 to 11 months post-treatment. Two of these, (WR-14 and 16) have not yet completed the twelve months follow-up (Table 5).

TABLE 1
LOCATION OF THE MUCOCUTANEOUS LESION

<u>LOCATION</u>	<u>NUMBER</u>	<u>PERCENTAGE</u>
SEPTUM	15/16	93.8
INFERIOR TURBINATE	8/16	50.0
MUCOSA	3/16	18.8
VESTIBULE	2/16	12.5

TABLE 2
DESCRIPTION OF THE MUCOCUTANEOUS LESIONS

<u>TYPE</u>	<u>NUMBER</u>	<u>PERCENTAGE</u>
GRANULOMATOUS	10/16	62.5
CRUST	5/16	31.3
INFLAMMATION	5/16	31.3
ULCER	5/16	31.3
ATROPHY	2/16	12.5
SCAR	1/16	6.3
PERFORATION	1/16	6.3

TABLE 3
PRESENTING SYMPTOMS OF MCL

<u>SYMPTOMS</u>	<u>NUMBER</u>	<u>PERCENTAGE</u>
Nasal obstruction	16/16	100.0
Rhinorrhea	7/16	43.8
Epistaxis	7/16	43.8
Itching	6/16	37.5
Pain	4/16	25.0
Bleeding	3/16	18.8
Soreness	1/16	6.3

TABLE 4ADVERSE REACTIONS TO PENTOSTAM

<u>SYMPTOMS</u>	<u>NUMBER</u>	<u>PERCENTAGE</u>
ARTHRALGIA	10/16	62.5%
MYALGIA	9/16	56.3
LIVER ENZYME INCREASE	7/16	43.8
EKG CHANGES	7/16	43.8
HEADACHE	5/16	31.3
LEUKOPENIA	5/16	31.3
NEUTROPENIA	5/16	31.3
NAUSEA	2/16	12.5
FEVER	2/16	12.5
ABDOMINAL PAIN	1/16	6.3
DIARRHEA	1/16	6.3
ANOREXIA	1/16	6.3
BRADYCARDIA	1/16	6.3

PATIENTS INCLUDED IN THE STUDY

<u>Number</u>	<u>Name</u>	<u>Sex</u>	<u>Age</u>
WR-1	A [REDACTED] P [REDACTED]	F	53
WR-2	P [REDACTED] de C [REDACTED]	F	23
WR-3	R [REDACTED] G [REDACTED]	M	21
WR-4	F [REDACTED] F [REDACTED]	M	29
WR-5	P [REDACTED] P [REDACTED]	F	61
WR-6	C [REDACTED] D [REDACTED]	M	29
WR-7	G [REDACTED] B [REDACTED] T [REDACTED]	M	18
WR-8	D [REDACTED] E [REDACTED] S [REDACTED]	F	28
WR-9	J [REDACTED] S [REDACTED]	F	31
WR-10	E [REDACTED] M [REDACTED]	F	21
WR-11	J [REDACTED] del C. T [REDACTED]	F	32
WR-12	A [REDACTED] L. V [REDACTED]	F	24
WR-13	I [REDACTED] S [REDACTED]	M	32
WR-14	F [REDACTED] R [REDACTED]	M	33
WR-15	C [REDACTED] A [REDACTED]	F	70
WR-16	P [REDACTED] P [REDACTED]	M	24

TABLE 5

FOLLOW-UP DATA

Patient No.	Post-Rx	1	2	3	4	5	6
WP-1 R. [REDACTED] P. [REDACTED]	H					I	
WP-2 P. [REDACTED] C. [REDACTED]	Skin I Nasal I						
WP-3 R. [REDACTED] G. [REDACTED]	Skin I Nasal I	Skin I Nasal I		Skin H Nasal I			
WP-4 F. [REDACTED] F. [REDACTED]	I	I		H			H
WP-5 P. [REDACTED] P. [REDACTED]	I	I				I	
WP-6 C. [REDACTED] O. [REDACTED]	I	I			I		H
WP-7 G. [REDACTED] B. [REDACTED] T. [REDACTED]	I	I		I			
WP-8 O. [REDACTED] S. [REDACTED]	I	I		I			I
WP-9 J. [REDACTED] S. [REDACTED]	Septal I Nostril I	I		I			H
WP-10 E. [REDACTED] M. [REDACTED]	I	I		I			I
WP-11 J. [REDACTED] T. [REDACTED]	Septal I Skin I Thigh H	P W H		R		P W H	
WP-12 R. [REDACTED] V. [REDACTED]	I		I		I		
WP-13 I. [REDACTED] S. [REDACTED]	I	I					
WP-14 F. [REDACTED] R. [REDACTED]	I	I		I			I
WP-15 C. [REDACTED] S. [REDACTED]	I	I				I	
WP-16 P. [REDACTED] P. [REDACTED]	Skin I Mucosal I			Skin I Mucosal I			

1672

LE 5

JP DATA

5	6	7	8	9	10	11	12	13	14	15	17
I				H			H			H	
			Skin I Nasal W			Skin I Mucousa W	Skin H Mucousa W	Skin H Mucousa W	Skin H Mucousa W		Skin H Mucousa W
						Skin H Nasal H					
	H						W		W		
I		I			H		H				
	H			H					H		
		H			H		H				
	I			H			H				
	H						H				
	I			H		H					
P W H					P W H						
		H		H				R			
	I				H						
I		I			H						
		H H									

3072